Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 4/20 | 0.43 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202002 | 0.86 | TSHR (0.44) | ECE1PTGDR2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL23361670 | 0.82 | FABP3 (0.51) | SMN1; SMN2KDM4EMEN1LMNAMAPT | |
| SCHEMBL3201031 | 0.79 | PARP1 (0.46) | ECE1KDM4ECTSASMPD3RAB9A | |
| SCHEMBL12503022 | 0.79 | PDPK1 (0.43) | PTGDR2PDPK1FABP4SCN9A | |
| SCHEMBL3201006 | 0.77 | PARP1 (0.47) | ECE1KDM4ECTSASMPD3RAB9A | |
| SCHEMBL3194094 | 0.75 | PDPK1 (0.42) | ECE1PTGDR2KDM4ELMNAHPGD | |
| SCHEMBL28932394 | 0.75 | MKNK1 (0.51) | KDM4EMEN1KMT2AMKNK1MKNK2 | |
| SCHEMBL30810276 | 0.74 | PARP1 (0.45) | SMN1; SMN2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3201989 | 0.74 | CTSA (0.45) | ECE1KDM4EMEN1LMNAMAPT | |
| SCHEMBL529977 | 0.74 | FABP4 (0.46) | SMN1; SMN2KDM4EMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795290-B2 | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | ECE1 1647/4885PTGDR2 4184/4885SMN1; SMN2 4020/4885 |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | ECE1 1647/4885PTGDR2 4184/4885SMN1; SMN2 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.